Special Issue

Nanomaterial-Based Contrast Agents for Biomedical Imaging

Message from the Guest Editors

Precision imaging is critical for the theranostics of diseases, as it provides insightful guidance for medical personnel to define pathological processes and manage diseases. Nowadays, nanomaterials have emerged as promising alternatives to conventional contrast agents for biomedical imaging since they offer high-fidelity imaging due to an improved delivery efficiency and accumulation in the diseased tissues. With the assistance of advanced imaging techniques, these nanomaterials could provide diverse imaging modalities, such as fluorescence imaging, photoacoustic imaging, magnetic resonance imaging, micro-CT imaging, X-ray imaging, etc. The theranostic performance of nanomaterials could be improved through the delicate tuning of the target ability, responsive release behavior, quantum yield, etc. Therefore, nanomaterials hold great promise for precision theranostics of diseases. This Special Issue aims to highlight the recent advances in the development of nanomaterials for contrast agents and biomedical imaging. Original research papers and reviews papers are all welcome.

Guest Editors

Dr. Bing Guo
School of Science, Harbin Institute of Technology, Shenzhen 518055, China

Dr. Tingting Peng
College of Pharmacy, Jinan University, Guangzhou 511436, China

Deadline for manuscript submissions

closed (31 March 2024)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/135804

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).